Sunday, September 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

View original at finance.yahoo.com
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna Roivant Sciences Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realiz…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Comirnaty sales represent approximately 2/3 of global COVID vaccine sales

    80% confidence
  • Outcome speaks to fundamental role that Genevant's foundational LNP technology played in enabling world's response to COVID-19 pandemic

    80% confidence
  • Moderna has finally acknowledged the seminal work of Arbutus scientists in enabling COVID-19 vaccines

    80% confidence
  • Settlement allows Genevant to put lengthy dispute behind them and remain focused on leveraging world-class nucleic acid delivery systems to bring innovative medicines to people

    80% confidence
  • It is gratifying for Genevant team to be recognized for pivotal contribution to restoring normalcy during COVID-19 pandemic

    80% confidence
  • Resolution with Moderna reduces uncertainty, validates Genevant IP estate and provides near term significant cash inflow

    80% confidence
  • Roivant will continue to be capital efficient with settlement proceeds, with additional $500 million authorized for share repurchases

    80% confidence
  • This is a transformative outcome for Arbutus and long-overdue recognition that COVID-19 vaccines would never have made it to the world without the seminal work of Arbutus scientists

    80% confidence
  • Arbutus scientists invented LNP delivery technology that changed the drug development landscape and enabled nucleic acids including mRNA to be used for medicines

    80% confidence
  • Section 1498 applies such that U.S. taxpayers should assume liability for Moderna's infringement of Genevant's and Arbutus' patents for sales made under government contracts

    80% confidence
  • If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com